IMPORTANT INFORMATION REGARDING THREE LOTS OF SANOFI PASTEUR’S 2014-2015 FLUZONE® QUADRIVALENT (INFLUENZA VACCINE) SUPPLIED IN MULTIDOSE VIALS

April 21, 2015

Dear Health Care Professional:

Sanofi Pasteur is committed to providing our customers with quality vaccines. As part of ongoing monitoring of the stability of all of our influenza vaccines, we have found that the antigen content of 3 lots of the 2014-2015 Fluzone Quadrivalent vaccine supplied in multidose vials has declined below the stability specification limit for 2 strains – A/Texas H3N2 and B/Brisbane (Victoria lineage). Stability tests for the A/California H1N1 and B/Massachusetts (Yamagata lineage) strains in these lots have remained within specification. You are receiving this communication because we have identified that you were shipped doses from 1 or more of these 3 lots.

There are no safety concerns related to these 3 lots and re-immunization is not necessary.

However, in response to the stability testing results, Sanofi Pasteur is initiating a voluntary recall of the remaining doses of 3 lots of Fluzone Quadrivalent vaccine:

<table>
<thead>
<tr>
<th>Lot Number:</th>
<th>Expiration Date:</th>
<th>Carton NDC:</th>
<th>Vial NDC:</th>
<th>Presentation:</th>
</tr>
</thead>
<tbody>
<tr>
<td>UI196AA</td>
<td>30JUN15</td>
<td>49281-621-15</td>
<td>49281-621-78</td>
<td>10-dose vials</td>
</tr>
<tr>
<td>UI190AC</td>
<td>30JUN15</td>
<td>49281-621-15</td>
<td>49281-621-78</td>
<td>10-dose vials</td>
</tr>
<tr>
<td>UI190AD</td>
<td>30JUN15</td>
<td>49281-621-15</td>
<td>49281-621-78</td>
<td>10-dose vials</td>
</tr>
</tbody>
</table>

This action does not impact any other lot of Fluzone Quadrivalent vaccine or any other presentations of Sanofi Pasteur’s Fluzone vaccines.

These lots passed all quality controls and met all licensed specifications required by the US Food and Drug Administration (FDA) at the time of shipping.

If you have any remaining doses from the above lots of Fluzone Quadrivalent vaccine, please do not use them and return the vaccine as outlined in the attached instructions.

We appreciate your attention to this matter.

Sincerely,

David P. Greenberg, MD
Vice President, Scientific & Medical Affairs and Chief Medical Officer

aNDC = National Drug Code.

MKT29375-1R